Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial

N. Colombo, D. S. McMeekin, P. E. Schwartz, C. Sessa, P. A. Gehrig, R. Holloway, P. Braly, Daniela Matei, A. Morosky, P. F. Dodion, M. H. Einstein, F. Haluska

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Background: This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer. Methods: Women with measurable recurrent or persistent endometrial cancer and documented disease progression were treated with ridaforolimus 12.5 mg intravenously once daily for 5 consecutive days every 2 weeks in a 4-week cycle. The primary end point was clinical benefit response, defined as an objective response or prolonged stable disease of 16 weeks or more.Results:In all, 45 patients were treated with single-agent ridaforolimus. Clinical benefit was achieved by 13 patients (29%), including 5 (11%) with confirmed partial responses and 8 (18%) with prolonged stable disease. All patients with clinical benefit response received ridaforolimus for more than 4 months. In this heavily pretreated population, the 6-month progression-free survival was 18%. Ridaforolimus was generally well tolerated: adverse events were predictable and manageable, consistent with prior studies in other malignancies. Overall, the most common adverse events were diarrhoea (58%) and mouth sores (56%); most common grade 3 or higher adverse events were anaemia (27%) and hyperglycaemia (11%). Conclusion: Single-agent ridaforolimus has antitumor activity and acceptable tolerability in advanced endometrial cancer patients. Further clinical evaluation of ridaforolimus is warranted.

Original languageEnglish
Pages (from-to)1021-1026
Number of pages6
JournalBritish Journal of Cancer
Volume108
Issue number5
DOIs
StatePublished - Mar 19 2013

Fingerprint

Endometrial Neoplasms
Sirolimus
ridaforolimus
Hyperglycemia
Disease-Free Survival
Mouth
Disease Progression
Anemia
Diarrhea
Population
Neoplasms

Keywords

  • clinical benefit response
  • endometrial cancer
  • mammalian target of rapamycin inhibitor
  • ridaforolimus
  • stable disease

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Colombo, N., McMeekin, D. S., Schwartz, P. E., Sessa, C., Gehrig, P. A., Holloway, R., ... Haluska, F. (2013). Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial. British Journal of Cancer, 108(5), 1021-1026. https://doi.org/10.1038/bjc.2013.59

Ridaforolimus as a single agent in advanced endometrial cancer : Results of a single-arm, phase 2 trial. / Colombo, N.; McMeekin, D. S.; Schwartz, P. E.; Sessa, C.; Gehrig, P. A.; Holloway, R.; Braly, P.; Matei, Daniela; Morosky, A.; Dodion, P. F.; Einstein, M. H.; Haluska, F.

In: British Journal of Cancer, Vol. 108, No. 5, 19.03.2013, p. 1021-1026.

Research output: Contribution to journalArticle

Colombo, N, McMeekin, DS, Schwartz, PE, Sessa, C, Gehrig, PA, Holloway, R, Braly, P, Matei, D, Morosky, A, Dodion, PF, Einstein, MH & Haluska, F 2013, 'Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial', British Journal of Cancer, vol. 108, no. 5, pp. 1021-1026. https://doi.org/10.1038/bjc.2013.59
Colombo N, McMeekin DS, Schwartz PE, Sessa C, Gehrig PA, Holloway R et al. Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial. British Journal of Cancer. 2013 Mar 19;108(5):1021-1026. https://doi.org/10.1038/bjc.2013.59
Colombo, N. ; McMeekin, D. S. ; Schwartz, P. E. ; Sessa, C. ; Gehrig, P. A. ; Holloway, R. ; Braly, P. ; Matei, Daniela ; Morosky, A. ; Dodion, P. F. ; Einstein, M. H. ; Haluska, F. / Ridaforolimus as a single agent in advanced endometrial cancer : Results of a single-arm, phase 2 trial. In: British Journal of Cancer. 2013 ; Vol. 108, No. 5. pp. 1021-1026.
@article{efbeae083ea447cc97b4c976376ba997,
title = "Ridaforolimus as a single agent in advanced endometrial cancer: Results of a single-arm, phase 2 trial",
abstract = "Background: This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer. Methods: Women with measurable recurrent or persistent endometrial cancer and documented disease progression were treated with ridaforolimus 12.5 mg intravenously once daily for 5 consecutive days every 2 weeks in a 4-week cycle. The primary end point was clinical benefit response, defined as an objective response or prolonged stable disease of 16 weeks or more.Results:In all, 45 patients were treated with single-agent ridaforolimus. Clinical benefit was achieved by 13 patients (29{\%}), including 5 (11{\%}) with confirmed partial responses and 8 (18{\%}) with prolonged stable disease. All patients with clinical benefit response received ridaforolimus for more than 4 months. In this heavily pretreated population, the 6-month progression-free survival was 18{\%}. Ridaforolimus was generally well tolerated: adverse events were predictable and manageable, consistent with prior studies in other malignancies. Overall, the most common adverse events were diarrhoea (58{\%}) and mouth sores (56{\%}); most common grade 3 or higher adverse events were anaemia (27{\%}) and hyperglycaemia (11{\%}). Conclusion: Single-agent ridaforolimus has antitumor activity and acceptable tolerability in advanced endometrial cancer patients. Further clinical evaluation of ridaforolimus is warranted.",
keywords = "clinical benefit response, endometrial cancer, mammalian target of rapamycin inhibitor, ridaforolimus, stable disease",
author = "N. Colombo and McMeekin, {D. S.} and Schwartz, {P. E.} and C. Sessa and Gehrig, {P. A.} and R. Holloway and P. Braly and Daniela Matei and A. Morosky and Dodion, {P. F.} and Einstein, {M. H.} and F. Haluska",
year = "2013",
month = "3",
day = "19",
doi = "10.1038/bjc.2013.59",
language = "English",
volume = "108",
pages = "1021--1026",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Ridaforolimus as a single agent in advanced endometrial cancer

T2 - Results of a single-arm, phase 2 trial

AU - Colombo, N.

AU - McMeekin, D. S.

AU - Schwartz, P. E.

AU - Sessa, C.

AU - Gehrig, P. A.

AU - Holloway, R.

AU - Braly, P.

AU - Matei, Daniela

AU - Morosky, A.

AU - Dodion, P. F.

AU - Einstein, M. H.

AU - Haluska, F.

PY - 2013/3/19

Y1 - 2013/3/19

N2 - Background: This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer. Methods: Women with measurable recurrent or persistent endometrial cancer and documented disease progression were treated with ridaforolimus 12.5 mg intravenously once daily for 5 consecutive days every 2 weeks in a 4-week cycle. The primary end point was clinical benefit response, defined as an objective response or prolonged stable disease of 16 weeks or more.Results:In all, 45 patients were treated with single-agent ridaforolimus. Clinical benefit was achieved by 13 patients (29%), including 5 (11%) with confirmed partial responses and 8 (18%) with prolonged stable disease. All patients with clinical benefit response received ridaforolimus for more than 4 months. In this heavily pretreated population, the 6-month progression-free survival was 18%. Ridaforolimus was generally well tolerated: adverse events were predictable and manageable, consistent with prior studies in other malignancies. Overall, the most common adverse events were diarrhoea (58%) and mouth sores (56%); most common grade 3 or higher adverse events were anaemia (27%) and hyperglycaemia (11%). Conclusion: Single-agent ridaforolimus has antitumor activity and acceptable tolerability in advanced endometrial cancer patients. Further clinical evaluation of ridaforolimus is warranted.

AB - Background: This open-label, multicentre, phase 2 trial evaluated the efficacy and tolerability of the mammalian target of rapamycin inhibitor ridaforolimus in women with advanced endometrial cancer. Methods: Women with measurable recurrent or persistent endometrial cancer and documented disease progression were treated with ridaforolimus 12.5 mg intravenously once daily for 5 consecutive days every 2 weeks in a 4-week cycle. The primary end point was clinical benefit response, defined as an objective response or prolonged stable disease of 16 weeks or more.Results:In all, 45 patients were treated with single-agent ridaforolimus. Clinical benefit was achieved by 13 patients (29%), including 5 (11%) with confirmed partial responses and 8 (18%) with prolonged stable disease. All patients with clinical benefit response received ridaforolimus for more than 4 months. In this heavily pretreated population, the 6-month progression-free survival was 18%. Ridaforolimus was generally well tolerated: adverse events were predictable and manageable, consistent with prior studies in other malignancies. Overall, the most common adverse events were diarrhoea (58%) and mouth sores (56%); most common grade 3 or higher adverse events were anaemia (27%) and hyperglycaemia (11%). Conclusion: Single-agent ridaforolimus has antitumor activity and acceptable tolerability in advanced endometrial cancer patients. Further clinical evaluation of ridaforolimus is warranted.

KW - clinical benefit response

KW - endometrial cancer

KW - mammalian target of rapamycin inhibitor

KW - ridaforolimus

KW - stable disease

UR - http://www.scopus.com/inward/record.url?scp=84875435116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875435116&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.59

DO - 10.1038/bjc.2013.59

M3 - Article

C2 - 23403817

AN - SCOPUS:84875435116

VL - 108

SP - 1021

EP - 1026

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -